EPO-4-Rhesus Study

NCT03104426 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Erythroblastosis, Fetal
Erythroblastosis Fetalis, Rh Disease
Erythroblastosis Fetalis Due to RH Antibodies
Erythroblastosis Fetalis Due to Isoimmunization

Interventions

DRUG: Darbepoetin Alfa

Sponsor

Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research

Collaborators

[object Object]